LGND Stock Analysis
LG
Neutral
Based on Eyestock quantitative analysis, LGND`s fundamental data and valuation indicate an investment grade of Neutral at the current time.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Moderate score
Upside
To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.
Undervalued
Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. The company is headquartered in San Diego, California and currently employs 76 full-time employees. The company is focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. The company has partnerships and license agreements with approximately 140 pharmaceutical and biotechnology companies and 400 programs are in various stages of commercialization, development, or research and are fully funded by its collaboration partners and licensees. The firm's OmniAb business segment is focused on enabling the discovery of therapeutic candidates for its partners by pairing antibody repertoires generated from its proprietary transgenic animals with its OmniAb business platform screening tools. The firm's Ligand core business segment is a biopharmaceutical business focused on developing or acquiring technologies that help pharmaceutical companies deliver and develop medicines. The OmniAb platform creates and screens diverse antibody pools and is designed to identify optimal antibodies.